As of early 2026, nearly half of U.S. Adults report difficulty affording healthcare costs, a persistent barrier to timely medical care that exacerbates chronic disease outcomes and strains public health infrastructure, according to the latest KFF tracking poll.
The Hidden Toll of Cost-Related Non-Adherence in Chronic Disease Management
When patients skip doses of antihypertensives, insulin, or statins due to cost, the physiological consequences are measurable and severe. Poor medication adherence driven by expense contributes to an estimated 125,000 preventable deaths annually in the U.S., with hospitalizations for heart failure and diabetic ketoacidosis spiking in quarters following insurance deductible resets. This phenomenon, termed cost-related non-adherence (CRNA), disproportionately affects adults aged 50–64 who are ineligible for Medicare yet lack employer-sponsored coverage, creating a coverage gap where fixed incomes collide with rising specialty drug prices.
Geographic Disparities in Access: From Rural Clinics to Urban Safety Nets
The burden of unaffordable care is not evenly distributed. In Mississippi and Texas—states with the highest uninsured rates and restrictive Medicaid eligibility—over 55% of adults report delaying care due to cost, compared to 38% in Massachusetts and Vermont, where expanded Medicaid and state subsidies mitigate financial toxicity. Federally Qualified Health Centers (FQHCs) serve as critical safety nets, yet even these facilities report strained formularies. a 2025 HRSA survey found 40% of FQHCs could not consistently stock GLP-1 receptor agonists for type 2 diabetes due to budget constraints, despite their proven cardiovascular benefits.
“We’re seeing patients split pills or take metformin every other day because they can’t afford the full dose—a practice with zero therapeutic benefit and real risk of glycemic volatility.”
In Plain English: The Clinical Takeaway
- Skipping medications to save money doesn’t just worsen symptoms—it can trigger emergencies like stroke or kidney failure that cost far more to treat.
- States that expanded Medicaid under the ACA show significantly lower rates of cost-related care delays, proving policy changes can protect both health and wallets.
- Always discuss cost concerns with your provider—lower-cost alternatives, patient assistance programs, or therapeutic equivalents may be available without compromising safety.
The Role of Biosimilars and Policy Levers in Reducing Financial Toxicity
Biosimilars—near-identical copies of biologic drugs like Humira® (adalimumab)—offer a pathway to lower costs without sacrificing efficacy. The FDA approved the first interchangeable biosimilar for insulin glargine in 2023, and by Q1 2026, biosimilars had captured 35% of the U.S. Adalimumab market, reducing average monthly costs by 45%. However, uptake remains uneven; in states with prior authorization barriers or provider unfamiliarity, adoption lags. The Inflation Reduction Act’s Medicare drug price negotiation provisions, set to take effect in 2026 for the first 10 selected drugs (including Eliquis® and Jardiance®), are projected to save Medicare beneficiaries $6 billion annually—but do not directly aid the under-65 uninsured.
“Policy solutions must extend beyond Medicare. Until we address coverage gaps for working-age adults, cost will remain a silent comorbidity in diabetes, hypertension, and heart disease.”
| Intervention | Target Population | Projected Annual Savings (U.S.) | Key Limitation |
|---|---|---|---|
| Medicare Drug Price Negotiation (IRA) | Medicare Part D enrollees | $6 billion | Excludes <65 population |
| Biosimilar Uptake (adalimumab) | Autoimmune disease patients | $4.2 billion | Varied state-level adoption |
| Medicaid Expansion (10 remaining states) | Low-income adults <65 | $3.8 billion (averted costs) | Dependent on state legislative action |
Contraindications & When to Consult a Doctor
This discussion applies to all patients managing chronic conditions where medication adherence is critical—including hypertension, type 2 diabetes, hyperlipidemia, and autoimmune disorders. There are no pharmacological contraindications to discussing cost concerns; in fact, avoiding such conversations increases the risk of therapeutic failure. Patients should seek immediate medical care if they experience symptoms like chest pain, shortness of breath, confusion, or extreme fatigue—signs that may indicate decompensation from missed doses. Routine follow-up every 3–6 months is advised to reassess regimen affordability and adjust therapy as needed.
Addressing healthcare affordability is not merely an economic issue—it is a clinical imperative. As biosimilars expand and policy levers evolve, the onus remains on healthcare systems to ensure that life-saving therapies are not only effective and safe, but accessible. Until then, transparent conversations about cost must be as routine as checking blood pressure.
References
- Kaiser Family Foundation (KFF). Health Care Debt Survey. February 2026. Https://www.kff.org/health-costs/survey/health-care-debt-survey-feb-2026
- U.S. Food and Drug Administration (FDA). Biosimilars Action Plan: Impact Report. January 2026. Https://www.fda.gov/drugs/biosimilars/biosimilars-action-plan-impact-report-2026
- Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report. 2025. Https://www.cdc.gov/diabetes/data/statistics-report.html
- Health Resources and Services Administration (HRSA). Health Center Program Annual Report. 2025. Https://bphc.hrsa.gov/data-reporting
- Congressional Budget Office (CBO). Effects of the Inflation Reduction Act on Medicare Drug Spending. March 2026. Https://www.cbo.gov/publication/58912
